Search Results for "therapeutic"

Alnylam is committed to providing the healthcare community with balanced, accurate, and high-quality information about our science, therapeutic areas, and products.

More than one search term is recommended to yield the most relevant results. By searching, you confirm that your query is unsolicited.

For more information about our FDA-approved therapies, please see the Full Prescribing Information:

Real-world experience with therapeutics for ATTR in the Canadian population

Targeting Glycolate Oxidase for the Treatment of Primary Hyperoxaluria Type 1: Development and Clinical Characterization of Lumasiran, an RNAi Therapeutic

Effect of RNAi Therapeutics Patisiran and Vutrisiran on Orthostatic Hypotension Due to Dysautonomia in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy

Amyloid-related imaging abnormalities in an ongoing Phase 1 study of mivelsiran, an investigational RNA interference therapeutic targeting amyloid precursor protein, in patients with Alzheimer’s disease

Outpatient Heart Failure Worsening in Patients with Cardiac Transthyretin Amyloidosis: Results from the APOLLO-B Trial

Impact of Baseline Polyneuropathy Severity on Vutrisiran Treatment Response in the Phase 3 HELIOS-A Study

RNAi Therapy in ATTRv Amyloidosis with Polyneuropathy (HELIOS-A): Patient-reported Experiences and Preferences

Vutrisiran Improved Outcomes Versus Placebo in Patients with Transthyretin Amyloidosis with Cardiomyopathy and Severe Chronic Kidney Disease: Post Hoc Analysis of HELIOS-B

Impact of Lumasiran on Long-Term Clinical Outcomes in Primary Hyperoxaluria Type 1 (PH1): a Cohort Simulation Model

NfL Levels Significantly Decrease in Response to Treatment with Patisiran or Vutrisiran in hATTR Amyloidosis with Polyneuropathy

Right Ventricular Free Wall Strain and Clinical Outcomes in Transthyretin Amyloid Cardiomyopathy and Effect of Vutrisiran: The HELIOS-B Study

Descriptive Analysis of Real-World Enrollment Data of Pediatric and Adult Patients From a Global Primary Hyperoxaluria Type 1 Registry (BONAPH1DE)

Left Atrial Strain and Clinical Outcomes in Transthyretin Amyloidosis with Cardiomyopathy: Insights from the HELIOS-B Trial on Vutrisiran Efficacy

ILLUMINATE Clinical Trial Program Overview

This infographic details the ILLUMINATE clinical trial program which investigates the treatment of Primary Hyperoxaluria Type 1 with lumasiran.

HELIOS-A: Results from the Phase 3 Study of Vutrisiran in Patients with Hereditary Transthyretin Mediated Amyloidosis with Polyneuropathy

Characteristics of Patients Treated with Givosiran in ELEVATE, a Global Observational Longitudinal Registry of Patients with Acute Hepatic Porphyria

HELIOS-A: Efficacy and safety of vutrisiran in patients with hATTR with polyneuropathy

Summary of the efficacy and safety results of vutrisiran compared to external placebo for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy, as published in the journal Amyloid, 2022.

Safety and Tolerability of Zilebesiran, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Obese Patients with Hypertension

Consistent antihypertensive efficacy of the RNA interference therapeutic zilebesiran: Subgroup results from the KARDIA-1 phase 2 study in patients with hypertension

Sustained blood pressure reduction with the RNA interference therapeutic, zilebesiran: Primary results from KARDIA 1, a phase 2 study in patients with hypertension

Multiple-Dose Results from an Ongoing Phase 1 Study of Mivelsiran, an Investigational RNA Interference Therapeutic Targeting Amyloid-Beta Precursor Protein for Alzheimer’s Disease

Safety and Tolerability of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients during Sodium Depletion or Irbesartan Coadministration

A Phase 1, Single Ascending Dose Study to Evaluate ALN-TTRsc04, a Next-Generation RNA Interference Therapeutic, in Healthy Participants for Potential Treatment of Transthyretin Amyloidosis

Durable Reductions in Circulating Angiotensinogen and Blood Pressure 6 Months after Single Doses of ALN-AGT, an RNA Interference Therapeutic Targeting Hepatic Angiotensinogen Synthesis, in Hypertensive Patients

For further information regarding your request, please connect with us by reaching out to your local Medical Science Liaison or contacting our Medical Information team.

Search Results for "therapeutic"

ILLUMINATE Clinical Trial Program Overview This infographic details the ILLUMINATE clinical trial program which investigates the treatment of Primary Hyperoxaluria Type 1 with lumasiran.

ILLUMINATE Clinical Trial Program Overview

This infographic details the ILLUMINATE clinical trial program which investigates the treatment of Primary Hyperoxaluria Type 1 with lumasiran.